We are pleased to share with you the launch of the first malaria therapeutic area data standard (TAUG-malaria), developed in close partnership with the Clinical Data Interchange Standards Consortium (CDISC). CDISC facilitates the development of standards that support clinical data gathering, exchang...

A new project funded by the French 5% Initiative on AIDS, Tuberculosis and Malaria has launched to provide close to real-time information on the prevalence and distribution of molecular markers of ACT drug resistance across the Mekong Greater Subregion.

Poor women in remote areas are the least likely to receive adequate health care. This is particularly true for regions with insufficient skilled health workers, such as in sub-Saharan Africa and South Asia.

New pharmacokinetic model has enabled revised dose regimen to safely treat all malaria patients with DP, including young children.

Researchers have investigated the efficacy and pharmacology parameters of the commonly used artemisinin combination therapy, artemether-lumefantrine (AL), in children with severe malnutrition and compared it with those who were not malnourished.

Study suggests deployment or rotation of multiple first-line antimalarial medicines will effectively treat malaria and maintain drug efficacy.

Over the past decade, the global health community has made huge gains in the battle against malaria. The World Health Organization’s annual World Malaria Report, out this week, highlights gains in vulnerable populations and challenges in global coverage.

In an article published today in The BMJ’s online Christmas edition, Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory, visits the history of falsified medicines and highlights what needs to be done to avert a problem that threatens us all.

A report from WHO provides the Greater Mekong Subregion with approaches necesssary to eliminate malaria in the region.

The growing inefficacy of the drugs currently available to treat visceral leishmaniasis (VL) needs to be addressed with harmonised research procedures, in order to discriminate resistant and susceptible strains, and establish a resistance ‘breakpoint’.

The Infectious Diseases Data Observatory will be at the American Society of Tropical Medicine and Hygiene 2016 Annual Meeting, in Atlanta, discussing the importance of responsible data sharing and poor quality medicines.

Over the next few months, the WWARN team will be busy travelling to international and regional conferences. We hope to see you there soon.

Earlier this year, WWARN conducted a survey of researchers who had contributed data to the WWARN platform. The aim was to understand researcher preferences about how your data are accessed and used thereafter. In response to this feedback, WWARN is developing new models of how data can be shared and...

We urge all involved in malaria studies and / or malaria clinical trials to use this opportunity to comment on the new CDISC Malaria Therapeutic Area User Guide (TAUG-Malaria).

The WorldWide Antimalarial Resistance (WWARN) is joining forces with other emerging and infectious disease communities through the newly-formed Infectious Diseases Data Observatory (IDDO).

Resistance to the artemisinin component of artemisinin combination therapies (ACTs),has emerged in parts of Southeast Asia. Locations with low malaria transmission and intense drug selection pressure are seen as potential hot spots for new outbreaks of drug resistant malaria. The identification of ...

P. falciparum malaria infection can be successfully treated using a combination of artemisinin derivatives and a partner drug, known together as artemisinin combination therapies (ACTs). However, signs of resistance to both the artemisinin derivative and partner drugs have emerged in many parts of t...

The proliferation of poor quality medicines has been described as a global pandemic that threatens the lives of millions. A new project will assess a variety of portable and handheld devices used to assess the quality of medicines.

A new article published in The BMJ outlines experiences and investigates the advantages and costs of different data sharing models.